Infliximab vs. adalimumab for Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 10, 2008, Pages 1265-1266

  Mulani, P ^a   Chao, J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LETTER; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REMISSION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; CROHN DISEASE; HUMANS;

EID: 54049158464     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03829.x     Document Type: Letter

References (4)

1. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007 26: 1509 20.
2. Rutgeerts P, Feagen BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004 126: 402 13.
3. Hanauer SB, Feagen BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet 2002 359: 1541 9.
4. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007 56: 1232 9.